Company GlucoTrack, Inc.

Equities

GCTK

US45824Q6061

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.67 ^USD	+0.60%		-4.02%	+27.72%

Jul. 01	GlucoTrack, Inc. announced that it has received $0.1 million in funding	CI
Jun. 20	Glucotrack Announces the Appointment of Andy Balo to Board of Directors	CI

GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.

Number of employees: 6

Managers	Title	Age	Since
Paul Goode CEO	Chief Executive Officer	56	20-12-16
James Cardwell DFI	Director of Finance/CFO	64	23-10-10
David Hammond CTO	Chief Tech/Sci/R&D Officer	-	-
James Thrower CTO	Chief Tech/Sci/R&D Officer	54	21-11-30
Drinda Benjamin SAM	Sales & Marketing	48	23-07-27
Mark Tapsak PRN	Corporate Officer/Principal	55	22-08-31

Members of the board	Title	Age	Since
Drew Sycoff BRD	Director/Board Member	57	19-07-07
Luis Malavé CHM	Chairman	61	Feb. 12
Robert Fischell BRD	Director/Board Member	95	09-12-31
Allen Danzig BRD	Director/Board Member	68	19-10-30
Paul Goode CEO	Chief Executive Officer	56	20-12-16
Shimon Rapps BRD	Director/Board Member	44	19-07-29
Erin Carter BRD	Director/Board Member	54	23-08-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,478,599	3,582,676 ( 65.39 %)	0	65.39 %

Name	Equities	%	Valuation
Ballantyne John A Revocable Trust 08/01/2017 18.62 %	1,020,033	18.62 %	2 M $
Alma Diversified Holdings LLC 9.404 %	515,188	9.404 %	1 M $
Sabby Management LLC 2.244 %	122,927	2.244 %	247 083 $
Paul Goode 1.456 %	79,764	1.456 %	160 326 $
Drew Sycoff 1.080 %	59,144	1.080 %	118 879 $
Luis Malavé 0.3633 %	19,902	0.3633 %	40 003 $
Erin Carter 0.3293 %	18,039	0.3293 %	36 258 $
Alerus Financial, NA 0.2529 %	13,856	0.2529 %	27 851 $
Mark Tapsak 0.1880 %	10,300	0.1880 %	20 703 $
Robert Fischell 0.1280 %	7,010	0.1280 %	14 090 $

GlucoTrack, Inc.

301 Route 17 North Suite 800

07070, Rutherford

+201 842 7715

http://www.glucotrack.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLUCOTRACK, INC.	+27.72%	9.15M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.56%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research